The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial intelligence-enabled medical device performance in real-world applications. This includes approaches to detect, assess and mitigate performance changes over time to help assure the devices remain safe and effective throughout their life cycle. The FDA is accepting comments at www.regulations.gov until Dec. 1. The notice follows a request by the Office of Science and Technology Policy issued Sept. 26 that seeks feedback on federal regulations that hinder AI development, deployment or adoption.

Headline
Jim VandeHei, CEO of Axios; Marc Boom, M.D., AHA board chair and president and CEO of Houston Methodist; Anne Klibanski, M.D., president and CEO of Mass…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
The Health Sector Coordinating Council’s Cybersecurity Working Group has released a guide on third-party artificial intelligence risk and AI supply…
Perspective
Public
Every day, we see more headlines and examples highlighting the impact of artificial intelligence on our lives. As with many transformational technologies,…
Headline
The Department of Health and Human Services March 31 announced that it is reverting a 2024 reorganization of health IT leadership and services. The dually…
Chairperson's File
Public
For decades, hospitals and health systems have used innovation to improve patient care and outcomes. We have seen dramatic improvements and know we can never…